# Moleculent

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moleculent

- Industry: Biotechnology
- Headquarters: Solna, Sweden
- Website: www.moleculent.com
- Total disclosed funding: $46M
- Latest round: Series A (Apr 28, 2026)
- Investors on record: 3

## About

Based in Solna, Sweden and founded in 2021, Moleculent AB is a biotechnology research platform that engages in cell and oncology research. In April 2026, Moleculent AB raised USD 20 million in series A funding led by Rubicon Healthcare Partners, with participation from ARCH Venture Partners and Eir Ventures. The company was co-founded by Olle Ericsson, and Fredrik Ross.
The company has developed technology to investigate high-plex interactions between cells, exposing the complex molecular mechanisms and signaling cascades behind a range of medical disorders. Moleculent's primary product is a platform that enables the direct measurement of cell-cell interactions inside their tissue milieu. This technique makes it possible to do at-scale functional proteomics by illuminating both the functional characteristics of healthy cells and the anomalies present in diseased cells.
The company’s revenue is generated by providing its functional profiling platform and related biological research solutions to biotechnology, pharmaceutical, and academic research organizations. Customers utilize its technology to study cell-cell interactions, tissue biology, and disease mechanisms.
The company plans to use the April 2026 funding to expand its early access program, build commercial operations in the US, and support the launch of its automated instrument.

## Funding rounds

- Series A, Apr 28, 2026, $20M — ARCH Venture Partners, Eir Ventures, Rubicon Healthcare Partners
- Series A, Jun 11, 2024, $26M — ARCH Venture Partners, Eir Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Eir Ventures (https://capitalatlas.ai/funds/eir-ventures) — Series A
- Rubicon Healthcare Partners (https://capitalatlas.ai/funds/rubicon-healthcare-partners) — Series A